Skip to content
Extending from June 19-25, the world’s largest air show takes place in Paris, France. Stealing spotlight from aerospace technology was a new and improved […]
SAF takes center stage at Paris Air Show Read More »
The Biotechnology Innovation Organization (BIO) International Convention is so much more than policy updates and panel sessions. The 2023 event, which returned to Boston
5 fun things that happened at the 2023 BIO International Convention Read More »
June 19 is World Sickle Cell Day, a day to highlight the work needed to address sickle cell disease (SCD) as well as the
World Sickle Cell Day: Could new treatments be here soon? Read More »
Antimicrobial resistance is one of the biggest global health challenges we face. Superbugs were linked to almost 5 million deaths worldwide in 2019, and
On AMR, ‘we need to be scared’ – and pass PASTEUR Read More »
Biopharma and biomanufacturing companies are working to address climate change, both in their own supply chains and more broadly, according to a June 7
How biopharma and biomanufacturing are changing the narrative on climate challenges Read More »
On June 13, the House Energy & Commerce Health Subcommittee held a hearing, Legislative Solutions to Bolster Preparedness and Response for All Hazards and
BIO’s Phyllis Arthur testifies on need to reauthorize PAHPA, pass PASTEUR Act Read More »
From vaccine-preventable viruses to antimicrobial-resistant infections, we “need to get ahead of disease,” said Emma Walmsley, CEO of GSK, at the 2023 Biotechnology Innovation
Getting ahead of disease – with technology and partnerships Read More »
Lawsuits filed in early June by Merck & Co. and the U.S. Chamber of Commerce seek to halt drug price controls established by the
Merck and U.S. Chamber file lawsuits to block IRA’s drug price controls Read More »
The Inflation Reduction Act (IRA) will introduce arbitrary changes in drug development as pharma companies are forced to work with complex new regulations that
BIO panels break down IRA’s challenges for drug makers and patients Read More »
On June 8, a Food and Drug Administration (FDA) advisory committee voted unanimously in favor of recommending traditional approval for LEQEMBI, the Alzheimer’s drug
FDA advisory committee endorses LEQEMBI Read More »
